CYTK
NASDAQCytokinetics Incorporated
Price$71.43+9.20 (+14.78%)
2026-03-042026-06-05
News · 26 weeks121-28%
2025-12-142026-06-07
Mix8290d
- Insider49(60%)
- Other14(17%)
- SEC Filings10(12%)
- Earnings4(5%)
- Offering3(4%)
- Analyst2(2%)
Latest news
25 items- INSIDERDirector Kaye Edward M. Md sold $223,172 worth of shares (2,933 units at $76.09), decreasing direct ownership by 22% to 10,283 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP, Chief Commercial Officer Callos Andrew sold $1,111,200 worth of shares (15,000 units at $74.08) and exercised 15,000 shares at a strike of $23.26 (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Parshall B Lynne sold $370,400 worth of shares (5,000 units at $74.08), decreasing direct ownership by 24% to 15,784 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in GermanyEuropean Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. Marking the first of several planned European launches, the availabi
- INSIDERPresident & CEO Blum Robert I sold $579,075 worth of shares (7,500 units at $77.21), decreasing direct ownership by 2% to 392,830 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Bhanji Muna was granted 2,851 shares, increasing direct ownership by 12% to 26,361 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Daly James M was granted 2,851 shares, increasing direct ownership by 735% to 3,239 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Harrington Robert Arthur was granted 2,851 shares, increasing direct ownership by 15% to 21,781 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Henderson John T was granted 2,851 shares, increasing direct ownership by 4% to 78,088 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Kaye Edward M. Md was granted 2,851 shares, increasing direct ownership by 28% to 13,216 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Parshall B Lynne was granted 2,851 shares, increasing direct ownership by 16% to 20,784 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Landry Robert E was granted 2,851 shares, increasing direct ownership by 39% to 10,184 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Wierenga Wendell was granted 2,851 shares, increasing direct ownership by 9% to 35,488 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Wysenski Nancy was granted 2,851 shares, increasing direct ownership by 9% to 33,917 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- SECSEC Form S-8 filed by Cytokinetics IncorporatedS-8 - CYTOKINETICS INC (0001061983) (Filer)
- SECCytokinetics Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CYTOKINETICS INC (0001061983) (Filer)
- PRCytokinetics to Participate in June Investor ConferencesSOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026 at 8:10 AM Eastern Time in New York, NY.Goldman Sachs 47th Annual Global Healthcare Conference: Fireside chat on Monday, June 8, 2026 at 9:20 AM Eastern Time in Miami Beach, FL. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://ir.cytokinetics.com/. The webcast replays will be archiv
- INSIDEREVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $264,915 worth of shares (3,500 units at $75.69) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics to Hold Annual Meeting of StockholdersSOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific Time at the Company's headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance. Stockholders of record at the close of business on March 31, 2026, are entitled to vote at Cytokinetics' Annual Meeting of Stockholders or to attend in person and submit questions to management. Stock
- ANALYSTCitigroup initiated coverage on Cytokinetics with a new price targetCitigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $99.00
- PRCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807 shares of common stock and 13,793 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in April and May 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant
- INSIDERPresident & CEO Blum Robert I sold $584,400 worth of shares (7,500 units at $77.92), decreasing direct ownership by 2% to 400,330 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)Third Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Company will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 29, 2026 from 8:00 AM to 5:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA. Registration for the symposium is now open and available at no cost to attendees; however, capacity is limited. Interested parties must register online by May 22, 2026, at https://climbsymposium.com/. "CLIMB has become
- PRCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 3:35 PM Eastern Time in New York, NY. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://ir.cytokinetics.com/. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical co
- PRCytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten. Collectively,
CYTK FAQ
7 questionsWhat does Cytokinetics Incorporated do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat...Where does CYTK stock trade?
Cytokinetics Incorporated (CYTK) is listed on NASDAQ.What sector and industry is CYTK in?
Cytokinetics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cytokinetics Incorporated go public?
Cytokinetics Incorporated (CYTK) completed its IPO in 2004.What are analysts saying about CYTK?
Cytokinetics Incorporated has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-05-19.What companies are similar to CYTK?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CYTK side-by-side with any of them on Quantisnow.How can I track CYTK on Quantisnow?
Quantisnow aggregates Cytokinetics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYTK to receive live email and push alerts on every new disclosure.